Zai Lab Limited (ZLAB)
(Delayed Data from NSDQ)
$21.85 USD
+0.76 (3.60%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $22.33 +0.48 (2.20%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ZLAB 21.85 +0.76(3.60%)
Will ZLAB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZLAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZLAB
Best Momentum Stocks to Buy for July 10th
New Strong Buy Stocks for July 10th
ZLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Other News for ZLAB
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Zai Lab announced data from Phase 1 study of ZL-1218
Zai Lab Announces Participation in September Investor Conferences
Zai Lab’s Solid Market Performance and Growth Prospects Justify Buy Rating